393 related articles for article (PubMed ID: 29906734)
1. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
2. Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy.
Ding PQ; Batra A; Xu Y; McKinnon GP; Cheung WY
Clin Colorectal Cancer; 2020 Sep; 19(3):209-218. PubMed ID: 32291245
[TBL] [Abstract][Full Text] [Related]
3. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
5. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
6. Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Tashiro J; Yamaguchi S; Ishii T; Suzuki A; Kondo H; Morita Y; Hara K; Koyama I
World J Surg Oncol; 2014 May; 12():145. PubMed ID: 24884880
[TBL] [Abstract][Full Text] [Related]
7. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer.
Alipour S; Kennecke HF; Woods R; Lim HJ; Speers C; Brown CJ; Gill S; Renouf DJ; Cheung WY
J Gastrointest Cancer; 2013 Jun; 44(2):203-10. PubMed ID: 23264206
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
11. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
12. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
[TBL] [Abstract][Full Text] [Related]
14. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
Dignam JJ; Polite BN; Yothers G; Raich P; Colangelo L; O'Connell MJ; Wolmark N
J Natl Cancer Inst; 2006 Nov; 98(22):1647-54. PubMed ID: 17105987
[TBL] [Abstract][Full Text] [Related]
16. The effect of smoking, obesity and diabetes on recurrence-free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy.
Croese A; Gartrell R; Hiscock R; Lee M; Gibbs P; Faragher I; Yeung J
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1346. PubMed ID: 33554476
[TBL] [Abstract][Full Text] [Related]
17. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
[TBL] [Abstract][Full Text] [Related]
18. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Zhang Y; Ma J; Zhang S; Deng G; Wu X; He J; Pei H; Shen H; Zeng S
Int J Colorectal Dis; 2015 Sep; 30(9):1173-83. PubMed ID: 26054387
[TBL] [Abstract][Full Text] [Related]
19. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
[Next] [New Search]
